| HOME >> BIOLOGY >> TECHNOLOGY |
HONG KONG, Dec. 20 /Xinhua-PRNewswire-FirstCall/ -- China Technology Development Group Corporation (Nasdaq: CTDC, "the Company" or "CTDC"), a provider of clean and renewable energy products and solutions focusing on solar energy business in China, today announced that it has completed another step in its strategic plan to focus the Company's management and operating resources on the principal business of solar energy.
On December 18, 2007, the Company disposed its subsidiary China Natures Technology Inc. ("China Natures") to an independent party for a total cash consideration of HK$10,000,000, pursuant to the sale and purchase agreement dated December 18, 2007 ("SPA"). The disposal of China Natures and the major terms of the SPA have been approved by the shareholders on the annual general meeting held on October 19, 2007. The net proceeds of the disposal will be used to further develop its core businesses.
Alan Li, Chairman and CEO of CTDC said, "The disposal of non-core business further advances our strategy of reshaping the Company around clean renewable energy sector which presents an exciting growth opportunity for the Company and our shareholders. This transaction will allow increased focus of management and financial resources on our core activities and will put the Company in a stronger position to move forward in the solar energy business."
About CTDC:
CTDC is a provider of clean and renewable energy products and solutions in the solar energy business in China. CTDC's ultimate principal shareholder is China Merchants Group ( http://www.cmhk.com ), one of the biggest state-owned conglomerates in China. For more information, please visit our website at http://www.chinactdc.com .
Forward-Looking Statement Disclosure:
This press release of the Company, which is a foreign private issuer,
on Form 6-K contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, and Section 21E of the
Securities Act of 1934. These statements relate to future events or the
Company's future financial performance. The Company has attempted to
identify forward-looking statements by terminology including "anticipates",
"believes", "expects", "can", "continue", "could", "estimates", "expects",
"intends", "may", "plans", "potential", "predict", "should", or "will" or
the negative of these terms or other comparable terminology. These
statements are only predictions, uncertainties and other factors may cause
the Company's actual results, level of activity, performance or
achievements to be materially different from any future results, level of
activity, performance or achievements expressed or implied by these
forward-looking statements. The information in this Report on Form 6-K is
not intended to project future performance of the Company. Although the
Company believes that the expectations reflected in the forward- looking
statements are reasonable, the Company does not guarantee future results,
level of activity, performance or achievements. The Company's expectations
are as of the date this Form 6-K is filed, and the Company does not intend
to update any of the forward-looking statements after the date this Report
on Form 6-K is filed to conform these statements to actual results, unless
required by law.
Enquiries:
Stephan Yao
General Manager, PR/IR Department
Tel: +852-3112-8461
Email: ir@chinactdc.com
'/>"/>
| SOURCE China Technology Development Group Corporation Copyright©2007 PR Newswire. All rights reserved |
Related biology technology :
1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |